Novo Nordisk to open Type 1 diabetes research and development center
PRINCETON, N.J. — In an effort to take Type 1 diabetes research to the next level, Novo Nordisk is set to open a research and development center in Seattle.
The center, slated to open this summer, will combine basic research and early proof-of-concept trials under one umbrella, the drug maker said. Additionally, the center will be staffed by approximately 20 researchers who will be supported by corporate functions in the United States and Denmark.
"Novo Nordisk has been passionate about helping people fight diabetes since the company was founded, and it is part of our mission to Take type 1 diabetes research to the next level," said Mads Krogsgaard Thomsen, EVP and chief science officer at Novo Nordisk. "With the new Type 1 diabetes R&D center, we hope to accelerate the process of finding new, innovative ways of treating people with this disease. Our vision is to prevent, treat and ultimately cure diabetes."
Vivere Health, Metro Medical Supply establish new specialty pharmacy company
FRANKLIN, Tenn. — Fertility clinic network Vivere Health has inked a deal with Metro Medical Supply to launch a specialty pharmacy company, Vivere said Monday.
Avanti Specialty Pharmacy Management will provide fertility pharmacy and related management services, Vivere said.
"We are pleased to partner with Metro Medical Supply, Inc., a proven provider of high-quality pharmacy services, in the creation of this new partnership for pharmacy management," Vivere CEO Joseph Cashia said. "Expanding our fertility offering to include specialty pharmacy management services is a natural extension of our model to provide fully integrated fertility care."
ReportersNotebook — Chain Pharmacy, 1/30/12
SUPPLIER NEWS — The Food and Drug Administration is streamlining the enrollment process for risk evaluation and mitigation strategies for a class of painkillers, the agency said. The FDA announced the approval of a single REMS for transmucosal immediate-release fentanyl drugs. The new system, which takes effect in March, will allow prescribers and pharmacies to enroll into one system instead of individual systems for each product. TIRF drugs include ProStrakan’s Abstral, Cephalon’s Fentora and Actiq, Archimedes Pharma’s Lazanda and Meda Pharmaceuticals’ Onsolis.
Teva Pharmaceutical Industries announced that Shlomo Yanai, president and CEO, will retire from his post in May. Yanai, who has served in this capacity for five years, has helped Teva expand from a mainly generics business to a more diversified pharmaceutical company, with expected 2012 revenue of approximately $22 billion, and an expanded footprint in the European, Asian and Latin America markets. Yanai will be succeeded by former Bristol-Myers Squibb executive Jeremy Levin. At Bristol-Myers, Levin had direct responsibility for strategy, alliances and transactions, and managed its portfolio of alliances.
The Food and Drug Administration has approved a Pfizer vaccine for Streptococcus pneumoniae in adults ages 50 years and older, the company said. Pfizer announced the FDA approval of Prevnar 13 (pneumococcal 13-valent conjugate vaccine [diphtheria CRM197 protein]) as a single-dose for adults.
Sandoz has launched a shampoo used to treat severe scalp psoriasis, the generic drug maker said. Sandoz announced the introduction of clobetasol propionate shampoo in the 0.05% strength, an authorized generic version of Galderma Labs’ Clobex. An authorized generic drug is a branded drug sold under its generic name, usually by a third-party company at a reduced price. Various versions of the shampoo had sales of about $54.9 million during the 12-month period ended in October 2011, according to IMS Health.
The Food and Drug Administration has approved a generic version of a drug for attention deficit hyperactivity disorder made by Actavis. Actavis announced the FDA approval of methylphenidate hydrochloride extended-release capsules in the 20-mg, 30-mg and 40-mg strengths, a generic version of Novartis’s Ritalin LA. Actavis said it was the first to file for regulatory approval of the drug in those three strengths, thus entitling it to 180 days of market exclusivity in which it will directly compete with the branded version. The drug had sales of $80.7 million during the 12-month period ended in September 2011, according to IMS Health.